glaucoma
Conditions
Interventions
None listed
Sponsors
Santen Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients diagnosed with glaucoma during the enrollment period Patients who were diagnosed with glaucoma and started a prescription of omidenepag isopropyl ophthalmic solution, FP agonists, or beta-blockers during the enrollment period Patients 18 years of age or older on the index date
Exclusion criteria
Exclusion criteria: Patients who were concomitantly prescribed glaucoma ophthalmic solutions other than the target medication on the index date Patients with a baseline period of less than 6 months Patients who were prescribed the same active pharmaceutical ingredient as the target drug during the baseline period Patients who underwent glaucoma surgery during the baseline period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment persistence rates of omidenepag isopropyl ophthalmic solution monotherapy group and FP agonist monotherapy group | — |
Countries
Japan
Contacts
Public ContactNaomi Otsuka
Santen Pharmaceutical Co., Ltd. Japan Medical Affairs
Outcome results
None listed